Mark S. Forman - 17 Nov 2025 Form 4 Insider Report for Ventyx Biosciences, Inc. (VTYX)

Role
Chief Medical Officer
Signature
/s/ Austin Rutherford, as Attorney-in-Fact
Issuer symbol
VTYX
Transactions as of
17 Nov 2025
Transactions value $
$3,090
Form type
4
Filing time
19 Nov 2025, 16:30:10 UTC
Previous filing
16 May 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Forman Mark S Chief Medical Officer 12790 EL CAMINO REAL, SUITE 200, SAN DIEGO /s/ Austin Rutherford, as Attorney-in-Fact 19 Nov 2025 0001922353

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VTYX Common Stock Award $3.09K +3K +100% $1.03 6K 17 Nov 2025 Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the Ventyx Biosciences, Inc. 2021 Employee Stock Purchase Plan ("2021 ESPP"), for the ESPP Purchase Period (as defined in the 2021 ESPP) of May 15, 2025 through November 14, 2025. This transaction is also exempt under Rule 16b-3(c).
F2 The relevant Offering Period (as defined in the 2021 ESPP) ended, and the shares were acquired, on the Exercise Date (as defined in the 2021 ESPP) of November 17, 2025.
F3 In accordance with the 2021 ESPP, these shares were purchased based on 85% of the closing price on May 15, 2025.